First Pulse: A Personal Journey in Cancer Research

First Pulse Projects in cooperation with Garnett McKeen Laboratory announces its first publication, First Pulse : A Personal Journey in Cancer Research, written by Merrill Garnett, edited by Bill Jones, with paintings by Joy Garnett. It includes 104 illustrated pages, a foreword by Professor Paul Bingham, Department of Biochemistry and Cell Biology, State University of New York at Stony Brook, and an appendix summarizing laboratory studies carried out with the support of the Carol M. Baldwin Breast Cancer Research Fund. For nearly forty years Dr. Merrill Garnett has pursued the goal of safe and effective treatment of cancer. According to his model, cancer results from the failure of cells to mature.This in turn is caused by a problem of energetics in the cell's metabolic processes. He has developed a chemical compound, palladium lipoic acid, that mimics an energy pathway present in normal cells, missing in cancer cells, and necessary to normal growth and health. This is the unusual story of his single-minded search. It describes Dr. Garnett's work and theory in a way that is stimulating and accessible to the scientist and non-scientist alike.

Dr. Merrill Garnett is the founder and CEO of Garnett McKeen Laboratory, Inc. Holding a D.D.S. from New York University, and graduate study in chemistry and biochemistry, Dr. Garnett has had research laboratories at the Central Islip State Hospital, Waldemar Medical Research Foundation, Northport Veterans' Administration Medical Center, and the High Technology Incubator of The State University of New York at Stony Brook.

Dr. Garnett's principle laboratory discoveries reveal the presence of corollary dynamics of the genetic code by which specific DNA coded segments and cell membranes exchange ultra-low frequency sinusoidal electrical currents. According to his theory, these pulsed currents are the basis of all physiological pulses and determine the polarization, charge and folding of enzymes, nucleic acids and membrane phospholipids. The restoration of these charge transfer pathways form the basis of several new methods of medicinal management.

Investigators at the University of Utah and Columbia University have collaborated in studies of his compound, DNA Reductase. This is the first non-toxic chemotherapeutic agent, a liquid crystal complex of palladium and lipoic acid. Other new drugs are also under development. Dr. Garnett has been issued three United States patents related to the treatment of tumors and psoriasis.